Three BMA awards for Karger Publishers

We are delighted to announce that three Karger titles received ‘Highly Commended’ awards by the British Medical Association in their prestigious 2016 Medical Book Competition:

In the category ‘Internal Medicine’

- **Tattooed Skin and Health**
  - Editors: J. Serup (Copenhagen); Kluger, N. (Helsinki); Baumler, W. (Regensburg)
  - X + 258 p., 110 fig., 85 in color, 25 tab., hard cover, 2015
  - www.karger.com/cupde

- **Retinal Pharmacotherapeutics**
  - Editors: Nguyen, Q.D. (Omaha, Nebr.); Rodrigues, E.B. (São Paulo); Farah, M.E. (São Paulo); Mieler, W.F. (Chicago, Ill.); Do, D.V. (Omaha, Nebr.)
  - XVI + 408 p., 83 fig., 71 in color, 33 tab., hard cover, 2016
  - www.karger.com/deoph

In the category ‘Oncology’

- **Immuno-Oncology**
  - Editors: Michielin, O.; Coukos, G. (Lausanne)
  - VI + 140 p., 8 fig., 5 in color, 11 tab., hard cover, 2015
  - www.karger.com/pritr

Karger titles which received awards in previous BMA Medical Book Competitions

- **Olszewski and Baxter’s Cytoarchitecture of the Human Brainstem**
- **Paediatric Bronchoscopy**
- **Macular Edema: A Practical Approach**

www.karger.com
Chemotherapy

International Journal of Experimental and Clinical Chemotherapy

Founded 1959 as “Chemothepapia” by H.P. Kuemmerle and P. Rentchnick

Editor-in-Chief
G. Minotti, Rome

Associate Editors
G. Delogu, Rome
G. Graziani, Rome

Editorial Board
A.M. Biroccio, Rome
C. Chiesa, Rome
S. Gemma, Siena
S. Horkovics-Kovats, Kundl
S. Kohno, Nagasaki
C. Landersdorfer, Parkville, Vic.
P. Linder, Geneva
K. Machka, Munich
P. Menna, Rome
E. Monti, Busto Arsizio
K.G. Naber, Straubing

R. Nau, Göttingen
P. Preziosi, Rome
E. Salvatorelli, Rome
M. Sanguinetti, Rome
G. Sava, Trieste
G.M. Shah, Quebec, Que.
F. Sörgel, Nuremberg-Heroldsberg
J.C. Stingl, Bonn
F. Van Bambeke, Brussels
M. Wilhelm, Nuremberg

The founder of chemotherapy

Paul Ehrlich
1854–1915
Submission
Before submission, please read the Guidelines for Authors for specific requirements for manuscript preparation. Manuscripts written in English are considered and should be submitted online at www.karger.com/che (a link leads you to the Submission Website).

Submission of an article implies author agreement with the below Conditions. To be considered for publication, all manuscripts must be accompanied by a cover letter signed by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission.

A Copyright Transfer Form, available on the Submission Website, with the corresponding author’s original (handwritten) signature must be received by the editorial office. Please print and sign the form, and upload it during submission (or fax or scan and email) to make it legally binding.

Names, postal and e-mail addresses of 4 international experts in the appropriate area of research should accompany each manuscript. At the Editors’ discretion, scientist(s) selected from this list may be invited to act as referee(s). Referees suggested should not be from the same institution as the author.


In case of problems with submission, please contact:
che@karger.com
S. Karger AG – Medical and Scientific Publishers
Editorial Office “Chemotherapy”
Allschwilerstrasse 10
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434

Conditions
All manuscripts are subject to editorial and peer review. Manuscripts are received with the explicit understanding that the work has not been published (wholly or in part), and is not under simultaneous consideration in any language elsewhere. Furthermore, all authors have made substantial contributions and confirm that they have seen and approve the manuscript submission. Submission of an article for publication implies the transfer of the copyright from the author to Karger Publishers upon acceptance. Accepted papers become the permanent property of Chemotherapy and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflict of Interest
Authors are required to disclose any sponsorship or funding arrangements related to the research presented in the manuscript and any possible conflicts of interest. A possible conflict of interest does not preclude consideration of a manuscript for publication, but the Editor might consider it appropriate to publish the disclosed information with the paper. All forms of support and financial involvement should be listed in the Acknowledgements section of the paper. The cover letter should certify that all forms of conflict of interest by all authors were clearly identified in the text.

Ethics
Research must comply with the guidelines for human studies and animal welfare regulations. Manuscripts reporting studies on human subjects should include evidence that the research was ethically conducted in accordance with the Declaration of Helsinki (World Medical Association; http://www.wma.net/en/30publications/10policies/b3/index.html). In particular, authors should state in the Materials and Methods section that subjects have given their informed written consent and that the study protocol was approved by an appropriate ethics committee. All patients should be identified by numbers or aliases, not by their real names. Authors should also state that animal experimentation was approved by an independent ethics committee. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. Karger Publishers defines plagiarism as reproduction of another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Sections
Authors should indicate in the cover letter which manuscript type is being submitted for publication:

Original Papers: Fully documented reports of original research that must describe full sets of significant, original experiments in current anti-infective and antitumor chemotherapy research. Abstract, Introduction, Materials and Methods, Results, and Discussion sections are required. Consideration for publication is based on originality, novelty, scientific soundness, and appropriate analysis (maximum 3,000 words, 80 references, plus tables/figures).

Reviews: Comprehensive, state-of-the-art papers covering a timely topic by experts in the field (maximum 4,000 words, plus tables/figures, references). Reviews are usually invited by the Editor but may be unsolicited. Authors are asked to contact the Editor-in-Chief before submission in order to avoid clashes with other pending reviews. All reviews are subject to peer review. An unstructured abstract of no more than 200 words is required.

Novel Insights from Clinical Practice: The journal only considers case reports that provide significant new insights into a clinical problem or an extremely uncommon clinical course. Submissions can be based around a case or a number of similar cases. The most important aspect of the presentation is that it should provide a new perspective on a recognized clinical scenario, or may represent an entirely new clinical condition. The novel aspects of the case(s) may be in the phenotype, the presentation, the investigation and/or the management. The manuscript should contain an unstructured abstract (maximum 150 words), introduction, case report and discussion section (maximum 2,000 words, maximum 2 tables or figures). Boxes containing bulleted points on Established Facts (what is already known) and Novel Insights (new information gained) are required on the first page of the report. These should highlight the novelty of the clinical observation.

Short Communications: Short reports, brief laboratory observations, and preliminary communications can be submitted for accelerated publication under Short Communications. They must present new findings of sufficient importance to justify their accelerated acceptance. Such communications should represent complete, original studies and should be arranged in the same way as full length manuscripts (maximum 1,600 words).

Letters to the Editor
Letters to the Editor are encouraged if they directly concern articles recently published in this journal. Accepted, the Editor reserves the right to submit such letters to the authors of the articles concerned prior to publication in order to allow them to respond in the same issue of the journal. In exceptional cases, Letters to the Editor may also address data published in another journal or general subjects related to matters discussed in the journal. No abstract is required (maximum 1,200 words).

Arrangement
The preferred word processing program is MS-Word. The cover letter, the manuscript, the tables and the figures must be submitted in separate files. The manuscript file must contain all the text elements in the following order: title page, abstract and key words, main text, acknowledgments, references, table and figure legends. Tables and figures should be submitted as separate files according to the instructions below. Automatic line numbering should be used consecutively from the title page through to the final page. All pages should be numbered, starting from the title page, including tables, figure legends and figures.

Title Page: The first page should contain the concise title of the article along with a short title for use as a running head, the full names of the authors and their affiliations (department, institute, hospital, university etc., where the work was conducted). The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Key words: Please supply 3–10 key words that reflect the content of the paper.

Abstract: Each original paper needs an abstract of up to 250 words structured with subheadings as follows: Background/Aims, Methods, Results, Conclusions. Structured abstracts are not needed for Reviews and Novel Insights from Clinical Practice.

Footnotes: Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgements: Include all sources of funding for the research presented in the manuscript and substantive contributions of individuals regarding the research or manuscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained when they are first used.

Units of measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lowercase) whenever possible. Registered trade names (first letter: uppercase) should be marked with the superscript registration symbol ® or ™ when they are first mentioned.

Figures and tables should be in PPT, AI or EPS format. Each figure and table must have a final resolution of 300 dpi individually. Figures and color figures must have a final resolution of 300 dpi after scaling to final size, line drawings 1,200 dpi. Color figures must be in RGB format. All figures should be in a common format such as PSD, TIF, PNG, EPS or WMF. Vector graphics should be in PPT, AI or EPS format.
Color Illustrations
Online edition: Color figures are reproduced free of charge. In the print version, the figures are reproduced in black and white. Reproduction costs for color figures in the text and figure legends should be avoided.
Print edition: Up to 6 color figures per page can be integrated within the text at CHF 960.00 per page.

References
Identity references in the text using Arabic numerals [in square brackets]. Do not alphabetize; number references sequentially in the order cited in the text. Material submitted for publication but not yet accepted should be referred to as [unpublished data] and should not be included in the reference list. References last should include only those publications which are cited in the text. Authors' surnames should be followed by their initials with no punctuation other than a comma to separate individual authors. Preferably cite all authors (if not possible include at least 3 authors followed by et al). Abbreviate journal names according to the list of journals indexed for MEDLINE on the NLM website. Also see International Committee of Medical Journal Editors: Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org).

Examples

Reference Management Software: The use of EndNote is recommended to facilitate formatting of citations and reference lists. The journal output style can be downloaded from http://endnote.com/downloads/styles.

Supplementary Material and Multimedia Files
Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 Mb in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figs.org under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.

English Language Editing
For authors whose native language is not English, use of a professional language editing service prior to submission can help to avoid delays with the review process.

Digital Object Identifier (DOI)
A DOI number will be available as a unique identifier on the title page of each article. DOIs are useful for identifying and citing articles published online without volume or issue information (for more information, see www.doi.org).

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. peer-review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution's internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:
• Be used for noncommercial purposes only
• Be linked to the final version on www.karger.com

Include the following statement:
“This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/doi-9 (DOI number).”

It is the author's responsibility to fulfill these requirements.

Manuscripts published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article. Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Kar- ger on the author’s behalf (see Funding Organizations (NIH etc.)).

For self-authoring: Author’s ChoiceTM (Gold Open Access) articles, see Author’s ChoiceTM.

Author’s ChoiceTM
Karger’s Author’s ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:
• Follow the terms of the relevant Creative Commons license
• Be linked to the final version on www.karger.com
• Include the following statement:

“*This is the final, published version of this article available at http://www.karger.com/doi-9 (DOI number).* It is the author’s responsibility to fulfill these requirements.
For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. A service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s ChoiceTM, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Copy Editing
Manuscripts accepted for publication by Karger Publishers are subject to copy editing.

Proofs
An email containing a link to download the proofs will be sent to the corresponding author. Proofs should be returned within 48 hours. Alterations made in proofs, other than the correction of printer’s (introduced) errors, are charged to the author and may require editorial approval.

Page Charges
There is no page charge for papers of 3 or fewer printed pages (including tables, illustrations and references). Au- thors are charged CHF 325.00 for each additional complete or partial printed page.

Reprints
An order form with a price list can be requested when returning the corrected proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

KARGER
E-Mail karger@karger.com
www.karger.com

© 2017 S. Karger AG, Basel
The Guidelines for Authors are available at:
www.karger.com/che_Guidelines
These essays on key issues in the natural sciences will appeal not only to

in this book Gottfried Schatz, the world-renowned biochemist

A new vision to understanding medicine

Editors: Karin Schenck-Gustafsson (Stockholm),
Paula R. DeC0la, Donald W. Pfaff (New York, N.Y.),
David S. Pisetsky (Durham N.C.)

In well-referenced chapters, experts cogently and concisely explain
how the incorporation of gender issues into research can affect the
medical understanding and treatment of heart disease, osteoporo-
sis, arthritis, pain as well as malaria among other conditions.
This intriguing and unique medical textbook provides readers with
a valuable new perspective on how to incorporate gender issues
into the different branches of medicine.

‘A collection of extraordinary essays’

GOTTFRIED SCHATZ

A MATTER OF WONDER

What Biology Reveals about Us, Our World, and Our Dreams

Where do we come from? Is our destiny determined by the genes
we inherit? In this book Gottfried Schatz, the world-renowned biochemist
and co-discoverer of mitochondrial DNA, gives lucid – albeit often
surprising – answers to universal questions and takes the reader on a fasci-
nating journey of discovery across the boundaries of scientific disciplines.

With passion and a keen sense of wonder he draws on philosophy,
cultural history and art to formulate his reflections on the mysteries of life.
These essays on key issues in the natural sciences will appeal not only to
scientists but to all inquisitive minds, regardless of educational and
professional background.

G. Schatz (Basel)
A Matter of Wonder
What Biology Reveals about Us,
Our World, and Our Dreams
Translated by A. Shields
XII + 190 p., 2 color fig., hard cover, 2011
CHF 29.00 / EUR 27.00 / USD 29.00

More information and sample essays at
www.karger.com/schatz
In 1964 Saul Roseman first described the phosphotransferase system (PTS) – a novel sugar-phosphorylating system in Escherichia coli. This compendium results from an international meeting held in Göttingen, Germany, during the summer of 2014 to commemorate the 50th anniversary of his discovery. A number of active researchers with a focus on the PTS reported their most recent findings concerning the structures, functions, mechanisms of action and physiological consequences of this complex system. The numerous aspects of the PTS, including a discussion regarding its impact on bacterial physiology, pathogenesis and ecology, are presented in this up-to-date compendium, which will provide a valuable source of information for many years to come.

Researchers, students and teachers of the physiology of archaea and bacteria will find this compendium an essential resource. It will serve as a valuable source of information for many years to come. Researchers, students and teachers of the physiology of archaea and bacteria will find this compendium an essential resource. It will serve as a valuable source of information for many years to come. Researchers, students and teachers of the physiology of archaea and bacteria will find this compendium an essential resource. It will serve as a valuable source of information for many years to come.
Contents

See the journal website for contents
The Journal of Innate Immunity is a bimonthly journal covering all aspects within the area of innate immunity, including evolution of the immune system, molecular biology of cells involved in innate immunity, pattern recognition and signals of ‘danger’, microbial corruption, host response and inflammation, mucosal immunity, complement and coagulation, sepsis and septic shock, molecular genomics, and development of immunotherapies. The journal publishes original research articles, short communications, reviews, commentaries and letters to the editors. In addition to regular papers, some issues feature a special section with a thematic focus.

Journal of Innate Immunity
Founded: 2008
Category: Basic and Clinical Research
Field of Interest: Immunology

Listed in bibliographic services, including:
PubMed/MEDLINE, Web of Science, Google Scholar, Scopus, Embase

2017: Volume 9
6 issues per volume
Language: English
ISSN 1662–811X
e-ISSN 1662–8128

Impact Factor: 4.273
5-Year Impact Factor: 4.505

More information at www.karger.com/jin

Selected contributions
- Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity: Kleinnijenhuis, J.; Quintin, J.; Preijers, F. (Nijmegen); Benn, C.S. (Copenhagen); Joosten, L.A.B.; Jacobs, C.; van Loenhout, J. (Nijmegen); Xavier, R.J. (Boston, Mass./Cambridge, Mass.); Aaby, P. (Copenhagen); van der Meer, J.W.M.; van Crevel, R.; Netea, M.G. (Nijmegen)
- M1 and M2 Macrophages: The Chicken and the Egg of Immunity: Mills, C.D. (Marine on St. Croix, Minn.); Ley, K. (La Jolla, Calif.)
- Inside-Out Signaling Pathways from Nuclear Reactive Oxygen Species Control Pulmonary Innate Immunity: Choudhary, S.; Boldogh, I.; Brasier, A.R. (Galveston, Tex.)
- Elie Metchnikoff, the Man and the Myth: Gordon, S. (Oxford)
- Some Important Milestones in the Field of Blood Clotting: Doolittle, R.F. (La Jolla, Calif.)
- Myeloid-Derived Suppressor Cells: Paradoxical Roles in Infection and Immunity: Dai, J.; El Gazzar, M.; Li, G.Y.; Moorman, J.P.; Yao, Z.Q. (Johnson City, Tenn.)
- C4a: An Anaphylatoxin in Name Only: Barnum, S.R. (Birmingham, Ala.)
194 In vitro Antibacterial Activity of 7-Substituted-6-Fluoroquinolone and 7-Substituted-6,8-Difluoroquinolone Derivatives
Leyva-Ramos, S.; de Loera, D. (San Luis Potosí); Cardoso-Ortiz, J. (Zacatecas)

159 Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview
Menna, P.; Salvatorelli, E. (Rome)

147 Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis
Kawaguchi, Y. (Otsu City/Kusatsu City); Hanaoka, J. (Otsu City); Hayashi, H.; Mizusaki, N.; Iihara, H.; Itoh, Y.; Sugiyama, T. (Gifu City)

151 Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution

172 Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells
Shen, X.; Zhi, Q.; Wang, Y.; Li, Z.; Zhou, J.; Huang, J. (Suzhou)

181 Expression of Activating Protein 4 and Its Relationships with Prognosis in Gastric Cancer
Sun, X.; Feng, Z.; Qu, Y.; Shao, J. (Harbin); Wei, N. (Shenyang)

199 Central Macular Thickness Monitoring after a Taxane-Based Therapy in Visually Asymptomatic Patients

169 Coronary Spasm after an Injection of Vincristine
Gros, R.; Hugon, V.; Thouret, J.-M.; Peigne, V. (Chambéry)

187 Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
Appio, L.; Landoni, C.; La Targia, M.; Bertolli, V.; Chiarucci, M.; Crovetti, G.; Vassenna, E.; Serio, G.; Bregni, M. (Busto Arsizio)

192 Do You Know Pixantrone?
Minotti, G.; Menna, P.; Salvatorelli, E. (Rome)